Skip to search formSkip to main contentSkip to account menu

BMS 641988

Known as: BMS-641988, BMS641988 
National Institutes of Health

Related topics

Related topics

3 relations
AR Antagonist BMS-641988

Broader (2)

Bridged Bicyclo Compounds, HeterocyclicImides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
ABSTRACT Introduction: Prostate cancer is the most common cancer in men. Regardless of the initial treatment of localized disease… 
2015
2015
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound… 
2011
2011
Effect of the novel anti-androgen ARN-509 on response and seizure in castration-resistant prostate cancer models.
28 Background: ARN-509 is a second-generation anti-androgen discovered in a screen to identify full androgen receptor (AR… 
2010
2010
Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Purpose: BMS-641988 is an androgen receptor antagonist with increased potency relative to bicalutamide in both in vitro and in… 
2010
2010
Chapter 6:Novel Androgen Receptor Antagonists for the Treatment of Prostate Cancer
The etiology and progression of prostate cancer is dependent on androgens and their signaling, which is mediated by the androgen… 
2008
2008
The design and synthesis of a novel series of androgen receptor antagonists leading to the discovery of the clinical candidate BMS-641988
1314 Carcinoma of the prostate (CaP) is the 2 nd leading cause of cancer-related death in men in the United States. Androgen… 
2006
2006
Preclinical assessment of gene expression and proteomic profiles promoted by the novel antiandrogen BMS-641988, bicalutamide and castration.
Proc Amer Assoc Cancer Res, Volume 47, 2006 5345 Complete androgen ablation (LHRH agonists and antiandrogens) is the gold… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)